Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.

OBJECTIVE Spleen tyrosine kinase (Syk) is involved in membrane-mediated signaling in various cells, including immune cells. It is overexpressed in T cells from patients with systemic lupus erythematosus (SLE), and its inhibition has been shown to improve T cell function as well as to improve disease manifestations in (NZB x NZW)F(1) lupus-prone mice and in patients with rheumatoid arthritis. While clinical trials examining Syk inhibition in patients with SLE are being considered, the aim of our experiments was to determine whether the therapeutic effects of Syk inhibition extend to other strains of lupus-prone mice and whether they result in improvement in skin disease and modification of established disease. METHODS Female MRL/lpr or BAK/BAX mice were studied. Starting either at age 4 weeks (before disease) or at age 16 weeks (after established disease) and continuing for up to 16 weeks, mice were fed chow containing the Syk inhibitor R788 or control chow. RESULTS We found that inhibition of Syk in MRL/lpr and BAK/BAX mice prevented the development of skin disease and significantly reduced established skin disease. Similarly, Syk inhibition reduced the size of the spleen and lymph nodes, suppressed the development of renal disease, and suppressed established renal disease. Discontinuation of treatment resulted in extended suppression of skin disease for at least 8 weeks and suppression of renal disease for 4 weeks. CONCLUSION Syk inhibition suppresses the development of lupus skin and kidney disease in lupus-prone mice, suppresses established disease in lupus-prone mice, and may represent a valuable treatment for patients with SLE.

[1]  W. Zou,et al.  SLP-76 Couples Syk to the Osteoclast Cytoskeleton1 , 2009, The Journal of Immunology.

[2]  Jens Timmer,et al.  Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. , 2009, Cancer research.

[3]  Y. Refaeli,et al.  Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. , 2009, Blood.

[4]  R. Aster,et al.  Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. , 2009, The Journal of clinical investigation.

[5]  J. Rivera,et al.  The tyrosine kinase network regulating mast cell activation , 2009, Immunological reviews.

[6]  T. Kurosaki,et al.  Tyrosine kinases and their substrates in B lymphocytes , 2009, Immunological reviews.

[7]  M. Weinblatt,et al.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.

[8]  María López-Bravo,et al.  Review in Vivo Induction of Immune Responses to Pathogens by Conventional Dendritic Cells , 2022 .

[9]  G. Tsokos,et al.  Cholera Toxin B Accelerates Disease Progression in Lupus-Prone Mice by Promoting Lipid Raft Aggregation1 , 2008, The Journal of Immunology.

[10]  D. Payan,et al.  An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. , 2008, Arthritis and rheumatism.

[11]  Stefano Monti,et al.  SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. , 2008, Blood.

[12]  C. Sheridan.  Small molecule challenges dominance of TNF-α inhibitors , 2008, Nature Biotechnology.

[13]  G. Tsokos,et al.  Syk kinase as a treatment target for therapy in autoimmune diseases. , 2007, Clinical immunology.

[14]  Feifei Zhao,et al.  Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. , 2007, Clinical immunology.

[15]  J. Ruland,et al.  Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17 , 2007, Nature Immunology.

[16]  D. Payan,et al.  R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[17]  P. Tak,et al.  A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[18]  S. Korsmeyer,et al.  Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  W. Swat,et al.  Vav3 regulates osteoclast function and bone mass , 2005, Nature Medicine.

[20]  S. Aronica,et al.  Altered Bax expression and decreased apoptosis in bone marrow cells of lupus-susceptible NZB/W mice , 2001, Lupus.

[21]  J. Kinet,et al.  Calcium mobilization via sphingosine kinase in signalling by the FcɛRI antigen receptor , 1996, Nature.

[22]  Tony Pawson,et al.  Syk tyrosine kinase required for mouse viability and B-cell development , 1995, Nature.

[23]  R. Geahlen,et al.  Stimulation of macrophage Fc gamma RIIIA activates the receptor-associated protein tyrosine kinase Syk and induces phosphorylation of multiple proteins including p95Vav and p62/GAP-associated protein. , 1994, Journal of immunology.

[24]  T. Yamamoto,et al.  Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling , 1994, The Journal of experimental medicine.

[25]  D. Cantrell,et al.  T-cell activation. , 1992, Trends in cell biology.

[26]  E. Gelfand,et al.  Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. , 2006, American journal of respiratory and critical care medicine.